CSPC Pharmaceutical Group Limited

1093.HK

HKSE

7.94

HKD

-0.11(-1.37%)

As of today

Overview Financials Dividends Ratios Discussions Analysis

CSPC Pharmaceutical Group Limited fundamentals

Overview Income Statement Balance Sheet Cash Flow

Key ratios

P/E Ratio

19.85

Price/Book

2.60

Debt/Equity

1.57%

Return on Equity

13.73%

Dividend Yield

3.63%

EBITDA

6.96B

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, the Americas, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.

Statements Highlights

AnnualQuarterly

Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024
Total Revenue	28,027,389,000	33,585,457,000	31,590,275,000	34,599,374,000	30,867,889,000
Gross Profit	20,996,572,000	25,472,247,000	22,726,458,000	24,397,354,000	21,599,258,000
Operating Income	5,472,152,000	6,249,258,000	6,759,633,000	7,680,123,000	5,709,957,000
Net Income	5,159,655,000	5,605,185,000	6,091,390,000	5,873,325,000	4,605,334,000
Total Assets	35,652,446,000	42,498,176,000	41,769,774,000	46,282,170,000	44,388,991,000
Total Current Liabilities	7,471,717,000	8,839,370,000	10,138,074,000	10,182,573,000	10,251,283,000
Total Equity	27,389,562,000	32,818,053,000	31,194,903,000	38,524,549,000	36,036,117,000
Free Cash Flow	5,908,106,000	3,743,216,000	5,320,416,000	2,285,748,000	1,855,788,000
Cash from Operations	6,739,610,000	4,636,627,000	7,627,064,000	4,178,815,000	4,534,664,000
Cash from Investing	-2,129,513,000	-637,326,000	-6,795,984,000	607,267,000	-3,858,200,000
Cash from Financing	-1,470,976,000	-2,196,606,000	-1,904,073,000	-2,300,981,000	-5,253,332,000
Net Change in Cash	4,012,563,000	1,800,251,000	-1,058,857,000	2,489,993,000	-4,573,469,000